ArriVent BioPharma, Inc.

government to manage federal debt limits, as well as the potential impact of other health crises on the global financial markets, may reduce the Company's ability to access capital, which could negatively affect its liquidity.

SEC original ↗ArriVent BioPharma, Inc. — 10-Q Quarterly report10-QAug 12, 2026

The Company s OCI includes, when applicable, unrealized gains and losses on available-for-sale debt securities.

SEC original ↗ArriVent BioPharma, Inc. — 10-Q Quarterly report10-QAug 12, 2026

Unrealized gains and losses on available-for-sale debt securities are recorded net of tax in accumulated other comprehensive income (loss) ( AOCI ), a component of stockholders equity, until realized.

SEC original ↗ArriVent BioPharma, Inc. — 10-Q Quarterly report10-QAug 12, 2026

The fair value was estimated using the Black-Scholes option-pricing model based on the following assumptions: Six Months Ended June 30, 2026 2025 Risk-free interest rate 3.72 % - 4.26 % 3.92 % - 4.37 % Expected term 5.5 - 6.1 years 5.5 - 6.1 years Expected volatility 74.0 % - 87.3 % 97.2 % - 98.3 % Expected dividend yield Unrecognized compensation cost for awards not vested as of June 30, 2026 was $ 79.5 million and will be expensed over a weighted-average period of 3.04 years.

SEC original ↗ArriVent BioPharma, Inc. — 10-Q Quarterly report10-QAug 12, 2026

(10) Common Stock At-the-Market Offering On February 3, 2025, the Company filed an automatic shelf registration statement on Form S-3ASR with the SEC pursuant to which the Company registered for sale an indeterminate amount of any combination of its common stock, preferred stock, debt securities, warrants, rights and units from time to time and at prices and on terms that the Company may determine, which is referred to as the 2025 WKSI Shelf .

SEC original ↗ArriVent BioPharma, Inc. — 10-Q Quarterly report10-QAug 12, 2026

No amounts have been drawn on this Term Loan as of June 30, 2026.

SEC original ↗ArriVent BioPharma, Inc. — 10-Q Quarterly report10-QAug 12, 2026

All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategy, plans for our product candidates, planned preclinical studies and clinical trials, results of clinical trials, future research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements.

SEC original ↗ArriVent BioPharma, Inc. — 10-Q Quarterly report10-QAug 12, 2026

, a Delaware corporation (the Company ), founded on April 14, 2021, is a clinical-stage biopharmaceutical company focused on identifying, licensing and globalizing top biopharma innovations from around the world to deliver important medicines to patients.

SEC original ↗ArriVent BioPharma, Inc. — 10-Q Quarterly report10-QAug 12, 2026

The Borrower s obligations are secured by a first priority, perfected lien on substantially all the property and assets of the Borrower, except for intellectual property (other than the security interest in proceeds from any intellectual property) and certain other customary excluded assets as set forth therein.

SEC original ↗ArriVent BioPharma, Inc. — 10-Q Quarterly report10-QAug 12, 2026

Some of the information contained in this discussion and analysis or set forth elsewhere, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties.

SEC original ↗ArriVent BioPharma, Inc. — 10-Q Quarterly report10-QAug 12, 2026

We seek to utilize our team s deep drug development experience to maximize the potential of our lead product candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, including ARR-217 ( MRG007 ) through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

SEC original ↗ArriVent BioPharma, Inc. — 10-Q Quarterly report10-QAug 12, 2026

Forward-looking statements are based on ArriVent s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict.

SEC original ↗ArriVent BioPharma, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025

Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled Risk Factors in our annual report on Form 10-K for the fiscal year ended December 31, 2024, to be filed with the Securities and Exchange Commission on March 3, 2025 and our other filings with the Securities and Exchange Commission.

SEC original ↗ArriVent BioPharma, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025

Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (Quarterly Report) contains forward-looking statements that involve risks and uncertainties.

SEC original ↗ArriVent BioPharma, Inc. — 10-Q Quarterly report10-QAug 12, 2026

These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

SEC original ↗ArriVent BioPharma, Inc. — 10-Q Quarterly report10-QAug 12, 2026

2 Table of Contents These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the Risk Factors section contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (SEC) on March 5, 2026 and elsewhere in this Quarterly Report.

SEC original ↗ArriVent BioPharma, Inc. — 10-Q Quarterly report10-QAug 12, 2026

In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

SEC original ↗ArriVent BioPharma, Inc. — 10-Q Quarterly report10-QAug 12, 2026